Cardinal Health, Inc.
CAH Healthcare Medical - Distribution NYSE
$198.83
$-0.36 (-0.18%)
Open: $199.76 | High: $200.26 | Low: $198.10 | Prev Close: $199.19
Market Cap: $47.24B
Volume: 1.7M | Avg: 2.5M
Last updated: December 05, 2025 at 10:00 PMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 470
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 29.99 |
| P/B Ratio | -16.44 |
| P/S Ratio | 0.20 |
| EPS | $6.63 |
| Beta | 0.64 |
| Shares Outstanding | 237.60M |
| 52-Week High | $214.93 |
| 52-Week Low | $114.60 |
| SMA 50 | $180.42 |
| SMA 200 | $155.62 |
| Dividend Yield | 1.02% |
| Annual Dividend | $2.03 |
| Next Earnings | January 29, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 3.7% |
| Operating Margin | 1.0% |
| Net Margin | 0.7% |
| ROE | -55.0% |
| ROA | 2.9% |
| Debt/Equity | -3.14 |
| Current Ratio | 0.96 |
| Quick Ratio | 0.52 |
Balance Sheet
| Total Assets | $53.12B |
| Total Liabilities | $55.76B |
| Total Equity | $-2,781,000,000 |
| Cash | $3.87B |
| Total Debt | $9.35B |
| Net Debt | $5.47B |
Income Statement
| Revenue | $222.58B |
| Gross Profit | $8.17B |
| Operating Income | $2.27B |
| Net Income | $1.56B |
| EBITDA | $3.11B |
| Revenue/Share | $984.50 |
Cash Flow
| Operating CF | $2.40B |
| CapEx | $547.00M |
| Free Cash Flow | $1.85B |
| Book Value/Share | $-11.47 |
| Tangible Book/Share | $-62.36 |
| Equity/Share | $-12.10 |
Technical Indicators
| RSI (14) | 35.44 Neutral |
| MACD |
6.61
Signal: 9.40
|
| Volatility | 47.55% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +56.87% |
| Sharpe Ratio | 1.93 Good |
| Volatility (Ann.) | 29.13% Moderate |
| CAH (1Y) | +56.87% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | +45.01% |
Sector Comparison (Healthcare)
| Metric | CAH | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 29.99 | 31.22 | 56% |
| P/B Ratio | -16.44 | -0.28 | 7% |
| ROE (%) | -55.00% | 10.90% | 7% |
| Net Margin (%) | 0.68% | 10.21% | 13% |
| Stock Score | 470 | 505.0 | 28% |
| 1Y Return (%) | +56.87% | +3.52% | 98% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAH | $198.83 | $204.86 | $207.80 | $207.72 | $180.42 | $155.62 | 35.44 | 6.61 | 47.55% | 2810152 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the CAH stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| CAH | Cardinal Health, Inc. (CAH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Neutral | seekingalpha.com | Read More |
| CAH | Cardinal Health, Inc. (CAH) Presents at Evercore 8th Annual Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| CAH | 4 Stocks With High Coverage Ratios Offer Safer Bets Going Into 2026 | Neutral | zacks.com | Read More |
| CAH | Potentially 12%-15% Consistent Income: Monthly Options Series (December 2025) | Neutral | seekingalpha.com | Read More |
| CAH | Best Dividend Aristocrats For December 2025 | Neutral | seekingalpha.com | Read More |
Company Information
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
| CEO | Jason Hollar |
| Employees | 47922 |
| Country | US |
| IPO Date | 1983-08-04 |
| Exchange | NYSE |
| Website | https://www.cardinalhealth.com |
| Sector | Healthcare |
| Industry | Medical - Distribution |
Similar Stocks (Healthcare - Medical - Distribution)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category